Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL2813938 | 0.97 | HCAR2 (0.36) | TSHRHPGDDNM1HCAR2ALDH1A1 | |
| SCHEMBL9480754 | 0.85 | TSHR (0.40) | TSHRHPGDDNM1NAAAHCAR2 | |
| SCHEMBL6274690 | 0.83 | TSHR (0.49) | TSHRHPGDNAAAHCAR2ALDH1A1 | |
| Urea SCHEMBL28950349 | 0.82 | TSHR (0.46) | TSHRHPGDDNM1HCAR2ALDH1A1 | |
| Pregabalin SCHEMBL27230104 | 0.82 | CACNA2D1 (0.49) | DNM1 | |
| SCHEMBL6272793 | 0.81 | TSHR (0.51) | TSHRHPGDNAAAHCAR2ALDH1A1 | |
| SCHEMBL11010126 | 0.78 | DNM1 (0.47) | TSHRDNM1ALDH1A1CNR1CNR2 | |
| SCHEMBL27829562 | 0.77 | HCAR2 (0.36) | TSHRHPGDNAAAHCAR2PLA2G2C | |
| SCHEMBL2398433 | 0.76 | DNM1 (0.41) | TSHRHPGDDNM1ALDH1A1CNR1 | |
| SCHEMBL5820402 | 0.75 | TSHR (0.45) | TSHRHPGDHCAR2ALDH1A1PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 445 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3307727-B1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES LLC (US) | 2023-10-04 | — | — | EP | claimed |
| EP-3592361-B1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING OCULAR INFLAMMATION | IACTA PHARMACEUTICALS INC (PR) | 2023-09-13 | — | — | EP | claimed |
| US-11090317-B2 | Aminophosphinic derivatives for preventing and treating eye inflammation | PHARMALEADS (FR) | 2021-08-17 | — | — | US | claimed |
| US-20210213036-A1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING EYE INFLAMMATION | PHARMALEADS (FR) | 2021-07-15 | — | — | US | claimed |
| US-10751332-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | ASANA BIOSCIENCES, LLC (US) | 2020-08-25 | — | — | US | claimed |
| US-10688113-B2 | Methods of treating eye pain with aminophosphinic derivatives | PHARMALEADS (FR) | 2020-06-23 | — | — | US | claimed |
| US-20190167701-A1 | Methods of Treating Eye Pain With Aminophosphinic Derivatives | PHARMALEADS (FR) | 2019-06-06 | — | — | US | claimed |
| US-20180344753-A1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING EYE PAIN | PHARMALEADS (FR) | 2018-12-06 | — | — | US | claimed |
| EP-3383403-A1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING EYE PAIN | Pharmaleads (FR) | 2018-10-10 | — | — | EP | claimed |
| WO-2018162860-A1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING OCULAR INFLAMMATION | PHARMALEADS (FR) | 2018-09-13 | — | — | WO | claimed |
| WO-2010017498-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | XENOPORT, INC. (US) | 2010-02-11 | — | — | WO | claimed |
| WO-2009138436-A1 | NOVEL AMINO ACID DERIVATIVES, METHOD FOR PREPARING SAME, AND THERAPEUTIC USE THEREOF | PHARMALEADS (FR) | 2009-11-19 | — | — | WO | claimed |
| US-20090216037-A1 | Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof | XENOPORT, INC. (US) | 2009-08-27 | — | — | US | claimed |
| US-7511158-B2 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT, INC. (US) | 2009-03-31 | — | — | US | claimed |
| JP-2007518723-A | — | — | 2007-07-12 | — | — | JP | claimed |
| US-7227028-B2 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT, INC. (US) | 2007-06-05 | — | — | US | claimed |
| US-20070037988-A9 | Formation of a thiocarbamate from a haloformic compound, dehalo-esterification, coupling an N-hydroxysuccinimide or secondary amide-containing drug; prodrugs of gabapentin and baclofen; improved bioavailability | XENOPORT, INC. | 2007-02-15 | — | — | US | claimed |
| EP-1716115-A2 | SYNTHESIS OF ACYLOXYALKYL CARBAMATE PRODRUGS AND INTERMEDIATES THEREOF | Xenoport, Inc. (US) | 2006-11-02 | — | — | EP | claimed |
| US-20050222431-A1 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT, INC. | 2005-10-06 | — | — | US | claimed |
| WO-2005066122-A2 | SYNTHESIS OF ACYLOXYALKYL CARBAMATE PRODRUGS AND INTERMEDIATES THEREOF | XENOPORT, INC. (US) | 2005-07-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167701-A1 | Methods of Treating Eye Pain With Aminophosphinic Derivatives | P2RX7, HRH3, P2RX6 | TSHR 1458/4885HPGD 2738/4885DNM1 3174/4885 |
| US-20050222431-A1 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | CPS1, ACMSD, NAAA | TSHR 3390/4885HPGD 345/4885DNM1 751/4885 |
| US-20090216037-A1 | Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof | CPS1, ACMSD, NAAA | TSHR 3390/4885HPGD 345/4885DNM1 751/4885 |
| US-20210213036-A1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING EYE INFLAMMATION | C5, CDK7, MAPK7 | TSHR 2849/4885HPGD 2605/4885DNM1 3316/4885 |
| US-10751332-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | KRAS, NRAS, RAF1 | TSHR 1261/4885HPGD 741/4885DNM1 1584/4885 |
| US-10688113-B2 | Methods of treating eye pain with aminophosphinic derivatives | P2RX7, HRH3, P2RX6 | TSHR 1458/4885HPGD 2738/4885DNM1 3174/4885 |
| US-11090317-B2 | Aminophosphinic derivatives for preventing and treating eye inflammation | C5, CDK7, MAPK7 | TSHR 2849/4885HPGD 2605/4885DNM1 3316/4885 |
| US-20180344753-A1 | AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING EYE PAIN | P2RX7, P2RY6, HRH3 | TSHR 2429/4885HPGD 3803/4885DNM1 3344/4885 |
| US-20070037988-A9 | Formation of a thiocarbamate from a haloformic compound, dehalo-esterification, coupling an N-hydroxysuccinimide or secondary amide-containing drug; prodrugs of gabapentin and baclofen; improved bioavailability | SLC6A13, SLC6A11, SLC6A1 | TSHR 928/4885HPGD 1302/4885DNM1 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.